ASX-LISTED MGC Pharma has been granted a formal Good Manufacturing Practice certification for its European production and compounding facility, following final tests on the first batch of its CannEpil epilepsy medication.
Receipt of the formal manufacturing licence also allows the company to produce additional medicinal cannabis based pharmaceutical products for use in clinical studies, research pipelines and product development.
The approval follows a successful $5 million capital raising in Apr, when MGC secured an approval for the development of a new cultivation and production facility in Malta.
MD Roby Zomer said the GMP certificate was one more step in the firm's "seed to pharma agenda".
MGC Pharma said CannEpil would soon be in patient's hands in Australia through the Authorised Prescriber Scheme.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 18
